INT12051

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1985
Last Reported 2007
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 11
Disease Relevance 0.42
Pain Relevance 2.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (Rnpep) extracellular space (Rnpep) aging (Rnpep)
extracellular region (Rnpep) Golgi apparatus (Rnpep) plasma membrane (Rnpep)
Anatomy Link Frequency
ASM 1
brain 1
Rnpep (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Opioid 2 99.84 Very High Very High Very High
Enkephalin 12 99.78 Very High Very High Very High
narcan 4 99.70 Very High Very High Very High
Dynorphin 1 98.56 Very High Very High Very High
analgesia 4 98.28 Very High Very High Very High
agonist 3 97.42 Very High Very High Very High
substance P 1 97.24 Very High Very High Very High
Somatostatin 1 96.72 Very High Very High Very High
tetrodotoxin 1 92.88 High High
tail-flick 1 91.36 High High
Disease Link Frequency Relevance Heat
Pressure And Volume Under Development 1 95.24 Very High Very High Very High
Carcinoma 1 94.92 High High
Sprains And Strains 15 78.32 Quite High
INFLAMMATION 25 76.04 Quite High
Cancer 10 5.00 Very Low Very Low Very Low
Diabetes Mellitus 5 5.00 Very Low Very Low Very Low
Aids-related Complex 5 5.00 Very Low Very Low Very Low
Nocardia Infection 5 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The enkephalin-degrading aminopeptidase is potently inhibited by opioid (alpha-neo-endorphin and dynorphin) as well as nonopioid (substance P, somatostatin, and angiotensin I) peptides in the range of 0.2-2.0 microM.
Negative_regulation (inhibited) of aminopeptidase associated with dynorphin, somatostatin, enkephalin, opioid and substance p
1) Confidence 0.36 Published 1985 Journal J. Neurochem. Section Abstract Doc Link 3886843 Disease Relevance 0 Pain Relevance 0.69
Diprotin A, an inhibitor of dipeptidyl aminopeptidase IV(EC 3.4.14.5) produces naloxone-reversible analgesia in rats.
Negative_regulation (inhibitor) of aminopeptidase IV associated with narcan and analgesia
2) Confidence 0.18 Published 1999 Journal Life Sci. Section Title Doc Link 10069492 Disease Relevance 0 Pain Relevance 0.68
Experiments with amastatin (1 microM) and thiorphan (1 microM), aminopeptidase, and neutral endopeptidase inhibitors, respectively, excluded the involvement of enzymatic degradation in Ang II-induced relaxation of ASM.
Negative_regulation (inhibitors) of aminopeptidase in ASM
3) Confidence 0.08 Published 2004 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15178697 Disease Relevance 0 Pain Relevance 0.19
OF4949, new inhibitors of aminopeptidase B.
Negative_regulation (inhibitors) of aminopeptidase B
4) Confidence 0.04 Published 1987 Journal J. Antibiot. Section Title Doc Link 3583919 Disease Relevance 0.19 Pain Relevance 0.08
Mutagenesis of any of the three zinc binding ligands of the HEXXHX18E conserved motif (H325, H329, E348 in rat Ap-B sequence or of the critical general base of the peptidase reaction E326 led to complete loss of aminopeptidase activity (Table 3).
Negative_regulation (loss) of aminopeptidase
5) Confidence 0.03 Published 2007 Journal BMC Biochem Section Body Doc Link PMC2241622 Disease Relevance 0.08 Pain Relevance 0.04
All mutations were found to abolish the aminopeptidase activity.
Negative_regulation (abolish) of aminopeptidase
6) Confidence 0.02 Published 2007 Journal BMC Biochem Section Abstract Doc Link PMC2241622 Disease Relevance 0.08 Pain Relevance 0.04
As expected, aminopeptidase inhibitors such as bestatine (Ki = 50 nM versus 100 nM for Ap-B purified from insect cells) or arphamenine A and B (Ki = 20 nM versus 40 nM for Ap-B purified from insect cells) work in micromolar concentrations.
Negative_regulation (inhibitors) of aminopeptidase
7) Confidence 0.02 Published 2007 Journal BMC Biochem Section Body Doc Link PMC2241622 Disease Relevance 0 Pain Relevance 0
The five larger hydrophobic patches of Ap-B (1000.070 Å2, 30 residues; 795.016 Å2, 31 residues; 645.299 Å2, 21 residues; 522.096 Å2, 15 residues; 519.139 Å2, 11 residues) are also represented on figure 6 and 8.
Negative_regulation (patches) of Ap-B
8) Confidence 0.02 Published 2007 Journal BMC Biochem Section Body Doc Link PMC2241622 Disease Relevance 0 Pain Relevance 0
Figure 1-C shows that there is a significant loss of desired His-rAp-B during the first washing.
Negative_regulation (loss) of rAp-B
9) Confidence 0.02 Published 2007 Journal BMC Biochem Section Body Doc Link PMC2241622 Disease Relevance 0.07 Pain Relevance 0
The PAR-2 agonist SLIGRL-NH2, administered intraperitoneally (i.p.) at 1-10 micromol/kg and 1.5-15 micromol/kg, in combination with amastatin, an aminopeptidase inhibitor, facilitated in vivo secretion of pancreatic and salivary amylase in a dose-dependent manner, respectively, in the mouse.
Negative_regulation (inhibitor) of aminopeptidase associated with agonist
10) Confidence 0.02 Published 2002 Journal Life Sci. Section Abstract Doc Link 12231404 Disease Relevance 0 Pain Relevance 0.15
LTNAM and TNLKM were as potent as LTN to inhibit brain aminopeptidase in vitro and ex vivo.
Negative_regulation (inhibit) of brain aminopeptidase in brain
11) Confidence 0.02 Published 1992 Journal Peptides Section Abstract Doc Link 1620657 Disease Relevance 0 Pain Relevance 0.71

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox